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Abstract
Wilson disease (WD) results from accumulation of copper and caused due to mutations in ATP7B, a copper 
transporting ATPase. Besides regular hepatic and neurological symptoms, WD patients occasionally manifest atypical 
symptoms due to unknown cause. To understand the molecular etiology of atypical WD manifestations, we screened 
COMMD1, a gene implicated in canine copper toxicosis, in 109 WD patients including those with atypical symptoms. In 
a patient showing apoptotic symptoms and high urinary copper surpassing normal WD levels, we identified a novel, 
putative mutation in COMMD1. Two other changes were also identified in the gene. We have examined genotype-
phenotype correlation between the detected changes and the atypical presentation of the WD patient.
Background
Wilson Disease (WD) is an autosomal recessive disorder
with a frequency of 1/5,000-1/30,000 live births world-
wide [1]. The disease is diagnosed on the basis of typical
symptoms and conventional biochemical indicators,
which include low serum concentrations of ceruloplas-
min (<20 mg/dl), elevated excretion of urinary copper
(>100 μg 24-hour urinary copper) and Kayser-Fleischer
ring in the cornea [2]. It is caused by mutations in the
ATP7B gene, which codes for a P-type ATPase with six
copper-binding regions [3]. The protein is localized on
the golgi membrane and is expressed primarily in the
hepatocytes where it transports copper from cytoplasm
to the bile canaliculi for excretion. In addition, the ATP7B
is essential for transport of copper from the cytosol into
the lumen of trans-Golgi network, where copper is uti-
lized for biosynthetic incorporation into secretory cop-
per-requiring enzyme, ceruloplasmin [4]. Mutations in
ATP7B impair copper export, resulting in accumulation
of the same mainly in the liver and brain and also in cor-
nea. Clinical manifestation varies from patient to patient
in terms of age of onset, organs involved, severity of the
disease and biochemical indications.
Although WD is an established monogenic disorder,
heterogeneity in phenotype is observed even among
patients harboring mutations in ATP7B that would affect
the mutant protein similarly (e.g. different truncation
mutations in the same region of the gene or exactly same
set of mutations in two sibs); no particular phenotype can
be attributed to a particular mutation [5]. Also, some
patients show symptoms atypical of WD [6]. Such obser-
vations led to the speculation that there might be modify-
ing loci, which modulate the phenotype resulting from
the aberration in the ATP7B. One would expect that
genes for proteins interacting either directly with ATP7B
or influencing it indirectly might fit the role of modifier
locus and genes of copper homeostasis pathway could
have such potential.
One of the candidate genes which might play the role of
a modifier locus is MURR1 (renamed COMMD1). In
dogs, especially in Bedlington Terriers, mutation in
COMMD1 causes canine toxicosis with symptoms of
high hepatic copper accumulation leading to hepatitis
and cirrhosis and eventual death between 2 and 6 years of
age, unless treated [7]. The causal founder mutation is a
deletion of exon 2 resulting in degradation of the protein
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p16) codes for a soluble 21-kDa protein, which is 88%
identical to its canine orthologue [9]. Though the exact
cellular role of COMMD1 is still uncharacterized, it
seems that it functions as a cytosolic as well as membrane
associated adapter protein linking lipids with other pro-
teins. It specifically binds phosphatidylinositol 4,5-bis-
phosphate (PtdIns(4,5)P2) through its C-terminal
domain. In native conditions, endogenous COMMD1
forms large oligomeric complexes both in the cytosol and
at the membrane; interaction with PtdIns(4,5)P2
increases the stability of oligomers [9]. It has been also
reported that COMMD1 interacts with the N-terminal
domain of ATP7B [10] and was shown to bind copper in
vitro through residues 61-154 (coded by exon 2) [11].
Knockout of COMMD1 by siRNA leads to elevated cop-
per retention in HEK293 [12]. Interestingly, XIAP (X-
linked Inhibitor of Apoptosis) has been observed to nega-
tively regulate COMMD1 protein levels by the formation
of K48 polyubiquitin chains on COMMD1 that promote
its degradation [12]. Recently, COMMD1 has been iden-
tified as an inhibitor of NF-κB signaling pathway [13].
Similar to many other proteins involved in NF-κB signal-
ing, COMMD1 also shuttles between cytoplasm and
nucleus. Two highly conserved Nuclear Export Signals
(NES) contained within amino acid 121-187 were identi-
fied in COMMD1 which are essential and sufficient for
its nuclear export. Mutations in the NES region caused
nuclear accumulation of COMMD1 and hence inhibition
of NF-κB activity [14]. Besides controlling NF-κB activity,
COMMD1 also interacts with HIF-1α and inhibits its
activity [15].
Close resemblance of copper toxicosis symptoms to
Wilson disease led to the idea of examining the role of
COMMD1 in WD patients particularly with atypical phe-
notypes [16-18]. Stuehler et al. found a correlation of
early age of onset in patients harboring H1069Q homozy-
gous mutation in ATP7B with the silent nucleotide
change c.492T>C (D164D) in COMMD1 [19]. However
in a study involving a heterogeneous cohort consisting of
Eastern European and Mediterranean WD patients, no
correlation was found between the change c.492T>C and
the age of disease onset. They also detected the change in
homozygous condition among normal individuals [20].
RNA studies to detect possible alteration of splice site,
revealed no changes in RNA size for this change [20]. In a
study involving Chinese Wilson disease patients, the par-
ticular nucleotide change could not be detected [17]. To
date, studies involving COMMD1 screening in Wilson
disease has failed to show any clear correlation between
any nucleotide change and a disease phenotype. To iden-
tify whether any biochemical change in WD correlates
with any change in COMMD1 or whether COMMD1 is
mutated in atypical Wilson disease patients, we screened
the three exons and a large part of the exon-intron
boundaries of COMMD1 in 109 patients.
Materials and methods
Wilson disease patients, mostly with neurological prob-
lems (106 out of 109), were examined at the Movement
Disorders Clinic, Bangur Institute of Neurosciences and
Psychiatry, Kolkata, India with referrals being made to
the Regional Institute of Ophthalmology, Kolkata and the
Gastroenterology and Pediatrics Departments, SSKM
Hospital, Kolkata, for ophthalmologic and hepatic cases,
respectively. The diagnosis was based on (a) clinically, on
the presence of neurological features like dystonia,
tremor, rigidity and bradykinesia and/or hepatic features
like signs and symptoms of acute or chronic liver failure,
cirrhosis of liver etc., and Kayser-Fleischer (K-F) ring in
the cornea; and (b) biochemically, on low serum cerulo-
plasmin (<20 mg/dl) and high 24-h urinary copper excre-
tion (>100 μg) [2], and on CT and MRI scanning where
applicable. Diagnosis was based on the entire profile, and
presence or absence of any one feature did not contribute
towards either diagnosis or exclusion thereof. Since most
of the patients are neurologic, liver biopsy was not car-
ried out as a diagnostic measure. On the basis of micro-
satellite marker and mutation analysis, we identified eight
pedigrees where the younger sib was presymptomatic.
We collected blood samples from 109 families that
included at least one patient in each family. Of all the
patients, ~95% of them had Kayser-Fleischer ring. The
internal review committee on research using human sub-
jects cleared the project after proper review as per the
regulations of the Indian Council of Medical Research.
Approximately 10.0 ml peripheral blood samples were
collected with informed consent of WD patients and
their family members. Genomic DNA was prepared from
fresh whole blood using the conventional phenol-chloro-
form method or salting-out method, followed by ethanol
precipitation after which the DNA was dissolved in TE
(10 mM Tris- HCl, 0.1 mM EDTA, pH 8.0). PCR was
done to amplify the exons and flanking regions of the
COMMD1 gene from the DNA of patients using primers
described in Table 1. PCR was carried out for each frag-
ment in a total volume of 25.0 μl as described above using
1.5-2.5 mM of MgCl2 (as appropriate) with 35 cycles of
denaturation at 94°C (30 s), appropriate annealing tem-
perature (varying between 50°C and 60°C) for 45-60 s and
an extension temperature of 72°C (60-90 s). Bi-directional
sequencing of the PCR products with the same set of
primers was done using an ABI 3100 Avant DNA
sequencer with dye-termination chemistry. Nucleotide
changes were detected by comparing the sequence
obtained in the chromatogram with the normal gene
sequence (NT_022184; Homo sapiens chromosome 2
genomic contig) using Pairwise BLAST [21].
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Three nucleotide changes were identified in COMMD1,
of which two represented reported synonymous changes
viz. c.492 GAT>GAC (Asp164Asp) [19] and a novel vari-
ant c.170+122C>T (IVS1+122C>T). The third one a non-
synonymous change (c.521 ACG>ATG; Thr174Met), also
represented a novel variant. The chromatogram showing
the change c.521 ACG>ATG is furnished in Fig 1.
Though the intronic variant appears to be inconsequen-
tial, the silent cSNP has been previously reported to be
associated with early onset WD phenotype [19]. Hence
our observations for both the coding sequence changes
are described below:
c.492 GAT>GAC (Asp164Asp)
We detected the change in two patients in heterozygous
condition. One patient was a compound heterozygote for
the ATP7B mutations c.2495_2496insG and
c.2298_2299insC, while ATP7B mutations in the other
patient are not characterized yet. Available phenotype
data for both the patients are furnished in Table 2. It was
interesting to note that age of onset (12 years) and the
ceruloplasmin levels (5.0 and 5.5 mg/dl) of these two
patients were strikingly similar. In addition, both the
patients showed marked extrapyramidal features of dys-
tonia, dysarthia and tremor; tremor was localized in the
upper limbs in both the patients. However, we have not
yet been able to establish a causal relationship of the
COMMD1 variant with specific disease phenotype since
we found the variant in two patients only.
c.521 ACG>ATG (Thr174Met)
The nucleotide variant identified in a single WD patient
represents a novel change that occurred in exon 3 of
COMMD1. The change represented a nonsynonymous
mutation, non-conservative in nature (i.e. polar to a non-
polar residue). Evolutionary conservation of the residue
(Thr) in Murr1 homologue was examined in different
species and it was found that like human, chimpanzee has
Threonine at the 174th amino acid position whereas in
cattle and dog it is the polar Lysine residue. Additionally,
the change resides in the region recently identified as the
second 'Nuclear Export Signal (NES)' i.e., amino acids
168-179 [14]. Screening the ATP7B gene revealed that the
patient harbored the Wilson disease causing mutations
c.813TGC>TGA (Cys271Stop) and c.2298_2299insC
(Pro767Pro-fs), both resulting in nonfunctional prema-
turely truncated protein. It is noteworthy to mention that
the father of the proband harbored the COMMD1-muta-
tion in heterozygous condition and had normal levels of
biochemical parameters and exhibited no signs or symp-
toms of the disease.
Signs and symptoms exhibited by the patient
The WD patient (W297, male, 9yr 6 months) was pre-
sented to the clinic with (a) difficulty in speaking and
slurring of speech, (b) drooling of saliva during laughing
and sleeping, and (c) abnormal posturing of all the four
limbs during daily routine activities (e.g. taking food,
walking and running). The patient had high neurological
predominance and mild hepatic symptoms. At eight years
of age he gradually developed slurring of speech and
extrapyramidal features like dystonia. The defects were
progressive in nature. His higher mental functions were
affected and he exhibited intellectual deterioration with
failing grades in school. Other complaints included focal
jerky involuntary movements during sleep and he had
difficulty in writing due to pain. KF ring was prominent
in both the eyes. The serum ceruloplasmin of the patient
was 7.0 mg/dl (normally >20 mg/dl) that further reduced
to 2.5 mg/dl even after administration of the d-pen-
Figure 1 Electropherogram showing the position of a novel puta-
tive mutation c.521 ACG>ATG (Thr174Met) in COMMD1. The al-
tered base (C>T) has been marked by an arrow. The nucleotide change 
and corresponding alteration in the amino acid are indicated at the 
bottom of the panel.
Table 1: The PCR primer sequences for scanning COMMD1 gene in WD patients
Exon Forward primer (5' - 3') Reverse primer (5' - 3') Amplicon size (bp)
1 GTGGTGGTTTTGCACAGGC TCCAAGCCGGAGACTACAG 301
2 TTCAGTGATTTAAGAGTCACTC GAATAGACAAGCTAACATGTAG 456
3 GAGTTTGGTCATGCCAGATG GTGAGAACCTCTGCACTGG 379
All these PCR primers were also used for sequencing COMMD1.
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response of the patient to chelation therapy.
We thought that two observations, as described below,
were striking in this patient, not common in the WD,
despite the fact that the patient responded well on treat-
ment with d-Penicillamine and his conditions improve-
ment with reduction in dystonic features.
(i) The 24-hours urinary copper was excessively high - 
1436 μg (normally <100 μg), which reduced to 880 μg 
after six months of therapy. In our patient pool the 24 
hours urinary copper level ranges from 90 - 380 μg. In 
seven of these patients, 24-hour urinary copper levels 
ranged between 90-100 μg.
(ii) The clinical record of the patient shows that his 
two lower incisor teeth were seen within seven days 
of birth.
In the present scenario involving the Wilson disease
patient with the putative COMMD1 mutation
Thr174Met (in addition to the ATP7B mutations), we
speculate that additional copper accumulation over the
general WD limits is due to the presence of one mutant
allele of COMMD1. This might have aggravated copper
accumulation is reflected by excessive level of urinary
copper.
Interestingly, Wilson disease patients do not exhibit
overt clinical features indicating apoptosis. It has been
reported that high copper accumulation increases XIAP-
Cu interaction, eventually leading to degradation of XIAP
[22]. It has also been shown that XIAP binds to
COMMD1 and regulates its cellular levels by functioning
as an E3 ubiquitin ligase for this protein and promoting
its proteasomal degradation [12]. Based on these reports
we speculate that the putative mutation (Thr174Met) in
COMMD1 caused increased copper accumulation and
hence degradation of XIAP which in turn decreased the
apoptotic threshold in the patient, upregulating Caspase-
3 mediated apoptosis. Dental apoptosis seems to be cas-
pase dependent and Caspase-3 has been shown to be
activated during dental apoptosis [23]. In our patient, it is
likely that lowering of apoptotic threshold and activation
of Caspase-3 might have played an important role in pre-
mature development of teeth. However, in this context, it
is important to mention that Bedlington Terriers with
homozygous knockout of COMMD1 leading to copper
toxicosis are not reported to have any defect in dentition.
Therefore, to decipher underlying molecular events,
appropriate experiments need to be done to examine
altered apoptosis, if any, by the COMMD1 mutation and
involvement of Caspase-3 in the process. It is also likely
that, since COMMD1 is reported to influence other cellu-
lar pathways involving NF-κB and HIF-1α, the mutant
protein might exert its effect by altering these cellular
events.
To date this is the first mutation to be reported in
COMMD1 which appears to influence pathogenesis of
the patient involving elevated copper accumulation. It is
interesting to note that despite multiple investigations to
identify mutations in COMMD1, not a single disease
causal mutation has been so far identified in this gene. It
is likely that, mutation in COMMD1, by itself is not suffi-
cient to cause a disease with a clinical manifestation.
Alternatively, since COMMD1 is involved in multiple
physiological processes, mutant COMMD1 on both the
alleles might cause pre-natal fatality.
In the present case, the occurrence of the COMMD1
mutation cosegregating with the compound heterozygous
ATP7B mutations appears to have enhanced Wilson dis-
ease phenotype. However, it is worth mentioning here
that out of 109 patients studied, we did not find any other
nucleotide variants in COMMD1 worthy to be labeled as
Table 2: Genotype-phenotype correlation in patients heterozygous for the COMMD1 change c.492 GAT/GAC
Features Patient W112 Patient W311
GENOTYPIC
COMMD1 c.492 GAT/GAC (heterozygous) c.492 GAT/GAC (heterozygous)
ATP7B c.2495_2496insG/c.2298_2299insC Not determined
PHENOTYPIC
Age of onset (yrs) 12 12
KF ring + +
Liver involvement History of jaundice Not apparent
Ceruloplasmin 5 mg/dl 5.5 mg/dl
24 hrs Urinary copper 98 μg 170 μg
Extrapyramidal features Dystonia, dysarthia, tremor in upper limbs
Liver function test (albumin:globulin; normal:1.7-1.9) 0.85 1.4
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similar studies, suggests that the COMMD1 variants do
not contribute to great phenotypic heterogeneity
observed in WD.
Limitations
Functional evidence for the role of the putative
COMMD1 mutation in increased urinary copper as well
as altered apoptosis in the WD patient would further sup-
port the study.
Conclusions
In this study, we report a single novel, putative mutation
in COMMD1 in one WD patient with atypical features.
The absence of any other prospective mutation in the
gene among 108 patients suggests that COMMD1 vari-
ants do not have any major contribution towards pheno-
typic heterogeneity observed in WD.
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